Jiahe Bio announces completion of $160 million Round B financing, high-rise capital investment

, Shanghai, China, June 1, 2020 - Jiahe Biopharmaceutical Co., Ltd(hereinafter referred to as Jiahe Bio) announces the completion of a $160 million round B financingJiahe Bio announced the completion of the $160 million Round B financingThe B-round financing has attracted top international medical investment funds and high-quality institutional investorsExisting shareholders continue to lead the way, with new investors including Temasek, China Resources Capital Life Sciences Fund, Haitong Kaiyuan International and Cavenham PEThis financing will be used for the clinical project advancement of existing product pipelines, the development of early innovative drugs, potential strategic cooperation at home and abroad, and preparation for the commercialization of products currently in the late stages of research and developmentCEO DrGuo Feng's speech" We are proud to receive recognition and support from existing shareholders and new investors in this round of financing2020 is a crucial year for JiaheWe are making a final push for a number of late-clinical product slots, while accelerating the development of innovative drugs in the field of oncology immunotherapyFounded in December 2007,JiaheJiahe Biopharmaceuticals Co., Ltdis a strong, research and development-driven, innovative biopharmaceutical companyThe company is committed to providing accessible medicines to patients who are not in a treatment needAt present, Jiahe has more than ten products in research, of which ten products have entered the clinical development stage The company's pipeline products are primarily located in the field of oncology and other major diseases, and have established a range of proven technology platforms for antibody drug research, development and manufacturing to serve patients in China and around the world Our management team has more than 20 years of industry experience with global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie Under its leadership, the company has established a highly integrated research and development team Jiahe has three offices and industrial bases in China - Zhangjiang in Shanghai, Yuxi in Yunnan and Beijing, and currently employs more than 400 people, 80% of whom are researchers forward-looking statements
This press release contains forward-looking statements relating to expected results with risks and uncertainties This statement is based on assumptions and estimates made by Jiahe Biopharmaceuticals Limited and is subject to risks and uncertainties Jiahe Bio herein declares that the Company undertakes no obligation to publicly update or revise any forward-looking statements in this press release for the above reasons as to the occurrence of new information, future events or other circumstances